KKR, a leading global investment firm, and Impilo, a Nordic healthcare investment firm, have announced the completion of their joint acquisition of Immedica Pharma, a pharmaceutical company headquartered in Stockholm and focused on the commercialization of medicines for rare diseases and specialty care products. Since its founding in 2018 by Impilo, Immedica has built an impressive portfolio and pipeline of drugs primarily within haematology, oncology and genetic & metabolic diseases for rare conditions with high unmet medical needs, generating revenues of EUR 100m and annual growth of more than 50%.
Read the full article: KKR Completes Joint Acquisition of Immedica Pharma //
Source: https://media.kkr.com/news-details/?news_id=22aa0102-931c-42ba-83ef-0261df8906c0&type=1